Table Of Contents

1. Introduction 15
1.1. Objectives Of The Study 15
1.2. Market Definition 15
1.3. Overview Of Europe Hla Typing Transplant Diagnostics Services Market 15
1.4. Currency And Pricing 16
1.5. Limitation 16
1.6. Markets Covered 17
2. Market Segmentation 19
2.1. Markets Covered 19
2.2. Geographic Scope 20
2.3. Years Considered For The Study 21
2.4. Currency And Pricing 21
2.5. Research Methodology 22
2.6. Primary Interviews With Key Opinion Leaders 25
2.7. Secondary Sources 26
2.8. Assumptions 26
3. Market Overview 27
3.1. Drivers 29
3.1.1. Technological Advancements In Hla Typing 29
3.1.2. Increasing Number Of Solid Organ And Stem Cell Transplantation Procedures 30
3.1.3. Increased Research Grants, Funds, And Public-Private Investments 30
3.2. Restraints 31
3.2.1. Weak Reimbursements For Organ Donation And Transplantation Procedures 31
3.2.2. Expensive Ngs And Pcr-Based Devices 31
3.3. Opportunities 32
3.3.1. Rising Healthcare Infrastructure In Emerging Nations 32
3.4. Challenges 33
3.4.1. Significant Gap Between Number Of Organs Donated And Organs Required Annually 33
3.4.2. Lack Of Trained Staff 34
4. Executive Summary 35
5. Premium Insights 37
6. Europe Hla Typing Transplant Diagnostics Services Market, By Technology 40
6.1. Overview 41
6.2. Next-Generation Sequencing (Ngs) 43
6.3. Polymerase Chain Reaction (Pcr) 44
6.3.1. Pcr Ssop (Sequence-Specific Oligonucleotide) 45
6.3.2. Pcr Ssp (Sequence-Specific Primer) 45
6.3.3. Pcr-Sbt (Sequencing Based Typing) 46
7. Europe Hla Typing Transplant Diagnostics Services Market, By End-User 47
7.1. Overview 48
7.2. Specialty Clinics 50
7.3. Hospitals 51
7.4. Transplant Centers 52
7.5. Academic Institutes 53
8. Europe Hla Typing Transplant Diagnostics Services Market, By Geography 54
8.1. Europe 54
8.1.1. Germany 63
8.1.2. France 65
8.1.3. U.K. 67
8.1.4. Italy 69
8.1.5. Spain 71
8.1.6. Switzerland 73
8.1.7. Netherlands 75
8.1.8. Belgium 77
8.1.9. Russia 79
8.1.10. Turkey 81
8.1.11. Rest Of Europe 83
9. Europe Hla Typing Transplant Diagnostics Services Market, Company Landscape 84
9.1. Company Share Analysis; Europe 84
10. Company Profiles 85
10.1. Proimmune Ltd. 85
10.1.1. Company Overview 85
10.1.2. Proimmune Ltd.; Company Snapshot 85
10.1.3. Product Portfolio 86
10.1.4. Recent Developments 86
10.2. Creative Biolabs 87
10.2.1. Company Overview 87
10.2.2. Creative Biolabs; Company Snapshot 87
10.2.3. Product Portfolio 87
10.2.4. Recent Developments 87
10.3. Histogenetics Llc 88
10.3.1. Company Overview 88
10.3.2. Histogenetics Llc; Company Snapshot 88
10.3.3. Product Portfolio 88
10.3.4. Recent Developments 88
10.4. The Ucla Immunogenetics Center 89
10.4.1. Company Overview 89
10.4.2. The Ucla Immunogenetics Center; Company Snapshot 89
10.4.3. Product Portfolio 89
10.4.4. Recent Developments 89
10.5. Admera Health 90
10.5.1. Company Overview 90
10.5.2. Admera Health; Company Snapshot 90
10.5.3. Product Portfolio 91
10.5.4. Recent Developments 91
10.6. Quick Biology 92
10.6.1. Company Overview 92
10.6.2. Quick Biology; Company Snapshot 92
10.6.3. Product Portfolio 92
10.6.4. Recent Developments 92
10.7. New York Blood Center 93
10.7.1. Company Overview 93
10.7.2. New York Blood Center; Company Snapshot 93
10.7.3. Product Portfolio 93
10.7.4. Recent Developments 93
10.8. The Sequencing Center 94
10.8.1. Company Overview 94
10.8.2. The Sequencing Center; Company Snapshot 94
10.8.3. Product Portfolio 95
10.8.4. Recent Developments 95
10.9. Bloodcenter Of Wisconsin 96
10.9.1. Company Overview 96
10.9.2. Bloodcenter Of Wisconsin; Company Snapshot 96
10.9.3. Product Portfolio 96
10.9.4. Recent Developments 96
10.10. Laboratory Corporation Of America Holdings 97
10.10.1. Company Overview 97
10.10.2. Laboratory Corporation Of America Holdings; Revenue Analysis 97
10.10.3. Product Portfolio 98
10.10.4. Recent Developments 98
10.11. Thermo Fisher Scientific Inc. 99
10.11.1. Company Overview 99
10.11.2. Thermo Fisher Scientific Inc. ;Revenue Analysis 99
10.11.3. Product Portfolio 100
10.11.4. Recent Developments 100
11. Related Reports 101